代谢相关脂肪性肝病是全球范围内肝病的主要原因，影响了全球近1/4的人口，尚无药物获批用于治疗该病。从临床前到临床，多个制药企业分别开展了针对抗代谢、抗凋亡和抗炎、抗纤维化等靶点的研究，取得了不同的结果。总结上述不同靶点化合物在临床II～III期的研究进展，阐明代谢相关脂肪性肝病治疗药物研发中的难点，提出可能的研究思路。

Metabolic-associated fatty liver disease (MAFLD) is the main cause of liver disease, which affected nearly one quarter of the world’s population, until now no drugs have been approved for the treatment of the disease. A lot of pharmaceutical companies have developed anti-metabolism, anti-apoptosis, anti-inflammatory or anti-fibrosis compounds for MAFLD treatment and showed different results from pre-clinical research to clinical research This article will summarize the research progress of these different target compounds in clinical phase II — III, clarify the difficulties in the development of therapeutic drugs for MAFLD, and propose possible research strategy.

R975